Aiming, Thanks for re-posting that message over on Yahoo. Concerning PTIE, I only have 425 shares, so I haven't been following it as closely as some other stocks. However, the recent press release seemed very confusing. It sounded like they've changed, or are trying to change, the endpoint in the Oxytrex trial from superiority to reduced side effects (physical dependence). The press release appears deceptive to me, since they never actually say that they're changing the endpoint, but use a pseudo Q+A format to state that the endpoint is reduced physical dependence, leaving it up to the reader to remember that it was previously superiority. To make matters worse, we come away not really knowing if the change in the endpoint was approved by the FDA or not ("the final analysis plan for this study was submitted to the FDA in early October ... the "prospectively defined" primary endpoint is reduction in physical depepdence and withdrawal symptoms..). That would seem to indicate that perhaps the FDA hasn't yet approved the change in the endpoint.
A hell of a way to run a railroad! It looks like that guy over on the Yahoo PTIE board ("Dunno") may be onto something with his harse criticism of PTIE management. I haven't followed the company for that long, but if this is typical of how they operate, I would be very cautious. The confusion over the Remoxy formulation is another red flag.
That said, they still might stumble through and ultimately get an approval, in spite of themselves. The stock is very cheap, and a small position in PTIE might still make sense, but I wouldn't make more than a token bet on a company whose management appears to be deceptive.
